Moorcraft Sing Yu, Chau Ian
The Royal Marsden NHS Foundation Trust, Gastrointestinal Unit, Department of Medicine , Sutton SM2 5PT , UK +44 020 8642 6011 ; +44 020 8643 9414 ;
Expert Opin Investig Drugs. 2014 Oct;23(10):1349-63. doi: 10.1517/13543784.2014.930126. Epub 2014 Jun 20.
The prognosis for patients with oesophagogastric (OG) cancer remains poor, with a median survival of approximately 9 - 11 months for patients with metastatic disease. However, a more personalised approach to treatment, using drugs tailored to the molecular characteristics of patients' tumours, has the potential to improve patient outcomes. Drugs targeting the ErbB family of receptors have been developed, but these have had varying degrees of success in clinical practice.
The authors provide an overview of the ErbB receptor family with regard to OG cancers. Furthermore, they evaluate the evidence from preclinical and clinical trials of therapeutics targeting this family, including monoclonal antibodies, tyrosine kinase inhibitors and novel agents.
Drugs targeting the ErbB family have been evaluated in OG cancer, with a notable success story in the case of trastuzumab, although there have been disappointing failures with anti-EGFR therapy. The response to targeted treatment remains variable and further biomarker research is essential to identify patients most likely to benefit from these therapies. The treatment of OG cancer remains challenging, but new anti-HER2 therapies and combination therapies hold promise for the future.
食管胃癌（OG）患者的预后仍然很差，转移性疾病患者的中位生存期约为9至11个月。然而，采用根据患者肿瘤分子特征定制的药物进行更个性化的治疗方法，有可能改善患者的治疗结果。已经开发出针对表皮生长因子受体（ErbB）家族受体的药物，但这些药物在临床实践中的成功程度各不相同。
作者概述了与OG癌症相关的ErbB受体家族。此外，他们评估了针对该家族的治疗药物的临床前和临床试验证据，包括单克隆抗体、酪氨酸激酶抑制剂和新型药物。
针对ErbB家族的药物已在OG癌症中进行了评估，曲妥珠单抗取得了显著成功，尽管抗表皮生长因子受体（EGFR）治疗也有令人失望的失败案例。对靶向治疗的反应仍然存在差异，进一步的生物标志物研究对于确定最可能从这些治疗中受益的患者至关重要。OG癌症的治疗仍然具有挑战性，但新的抗人表皮生长因子受体2（HER2）疗法和联合疗法有望为未来带来希望。
